



iPAAC
INNOVATIVE PARTNERSHIP
FOR ACTION AGAINST CANCER


WP5 Cancer screening

Satu Lipponen, WP5 leader, Ahti Anttila, WP5 scientific advisor, Kaarina Tamminiemi, coordinator – Cancer Society of Finland, Finnish Cancer Registry



Co-funded by
the Health Programme
of the European Union

- 1 Strategies for early diagnosis of cancer
 - 2 Effective solutions for population-based screening programmes
 - 3 Cancer prevention & health promotion: implementation of the European Code Against Cancer
- Inequality a **cross-cutting** theme integrated in above mentioned tasks



MAIN OBJECTIVES OF WP5 INCLUDE:



- to identify barriers to early detection and its management
- **to strengthen quality aspects of population-based screening policies by developing decision-making tools, including cost-effectiveness and analysis of harms and benefits**
- **to investigate the possibilities and barriers of risk-based cancer screening programmes**
- to monitor and review **European Code Against Cancer** in the long-term perspective focusing on policy tools and guidance to the public
- to review and plan better endorsements of recommendations within the European Code Against Cancer and to increase aspects of health for all and in every policy for local, regional and EU-level




WP 5.3 SCOPE AND WORKING MODE

- Focus on implementation rather than recommending new areas > EU Council recommendation 2003/878/EC (2003)
https://ec.europa.eu/jrc/sites/jrcsh/files/2_December_2003%20cancer%20screening.pdf
- Based on and continuing work from screening chapter of CANCON Joint Action
- Risk-stratification for modifying population based programmes
- Collaboration, co-creation, across Member States and with Association of European Cancer Leagues ECL and International Agency for Research on Cancer IARC
- Looking for bridges between prevention, early diagnosis and screening programmes
- Providing updates of two potential new programmes: lung cancer and prostate cancer



Priorities for cancer screening policies

IPAAC WP5 TIMELINE



Conference reports early diagnosis and cancer screening from ipaac.eu>WP5

CONFERENCE REPORTS

The WP 5 has 3 tasks addressing early diagnosis, cancer screening and health promotion and each task will end with a dedicated conference with **co-creation**. Co-creation aims at facilitating **discussion and dialogue**, increasing engagement across participants and fostering **problem solving and giving insights** to identify best policies. These specific events will be formulated into **comprehensive reports**, reflecting perspectives from all partners of the WP5.


- 2019 co-creational conference in Budapest: early diagnosis
- 2019 co-creational conference in Helsinki; cancer screening
- I online meetings 28 & 29.4.2020 (ECAC)
- **II online meeting 22.2.2021 (cancer prevention, health promotion)**

WP5 CANCER SCREENING REPORT



The report includes

- Definitions and criteria for cancer screening
- Key elements for effective and innovative implementation of population-based cancer screening.
- Reducing social inequalities in cancer screening
- Risk-stratified screening: criteria and innovations
- On what basis can we decide to modify a screening programme with a risk-stratified approach? Case of breast cancer
- Potential of new cancer screening programmes: updated evidence on lung and prostate cancer screening
- Current status of cancer screening in EU and need to update
- Group work on new strategies for cancer screening
- Discussion and conclusions



Authors: Ahti Anttila, Deependra Singh, Satu Lipponen, Stefan Lönnberg, Clarissa Bingham, Kaarina Tamminiemi, Ana Molina-Barceló, Marta Hernández-García, Paolo Giorgi Rossi, Marco Zappa



WHAT IS SCREENING AND OTHER QUESTIONS


- Is it a single test you take?
- Is it surveillance of a patient with a very high cancer risk?
- Is it personal screening or public health measure or both?
- How do you modify screening?
- How is screening implemented in the European Union?
- How can we further improve screening?
- How do we introduce new activities?
- What sort of legislation and data management is needed?
- Effects of pandemic to the screening programmes?

DEFINITIONS FOR CANCER SCREENING

- Screening refers to the use of relatively simple medical tests across an apparently **healthy population in order to identify individuals who have a clinically unrecognized disease or defect**. Persons with a positive or suspicious finding must be referred for a confirming diagnosis and, if necessary, to treatment (Wilson & Jungner, 1968)
- Importance of evidence on an acceptable **balance between benefit and harm**, because death cause by the screened disease is rare, compared with clinical high-risk patient groups. Screening can turn an apparently healthy individual to a cancer patient
- Risk-stratified screening (=selective screening in a population-based approach, Wilson & Jungner, 1968) aims to improve the screening programme by **modifying screening policies within the population-based programme** based on **individual-level disease or mortality risk**

MODIFICATION STEP BY STEP

- Risk-stratified screening is an example of innovation and development in the domain of cancer screening, and it is important to develop further criteria for it from the policy-making perspective
- **Surveillance** as close and continuous observation of high-risk patient groups identified largely from their clinical environment or their close relatives.
 - The EU Council recommendation on cancer screening (2003): due account should be taken of specific needs of persons who may be at higher cancer risk for particular reasons (e.g. biological, genetic, lifestyle and environmental, including occupational reasons). No further advice was provided on this topic yet
 - EU level guidelines and policy advice
 - Technological possibilities to improve data management
 - Special focus on inequalities
 - Social innovations – everyday inventions like flexible tools for changing invitation time, reminders
 - Governance is key to effective cancer screening (CANCON)



<https://cancercontrol.eu/archived/guide-landing-page/guide-cancer-screening.html#a4>

Satu Lipponen, iPAAC webinar 14 January, 2021



ALL CONTRIBUTORS



Invited experts

Partha Basu, International Agency for Research on Cancer, France

Kaisa Lähteenmäki-Smith, MDI Finland

Mark Dobrow, University of Toronto, Canada

Robert JC Steele, University of Dundee, United Kingdom

Facilitators Thematic groups, Technical meeting 4.12.2019

Stephanie Xuereb, Primary Healthcare, Ministry for Health, Malta

Partha Basu, International Agency for Research on Cancer, France

Isabel Portillo-Villares, The Basque Health Service – The Basque Ministry of Health, Spain

Ana Molina-Barceló, Fisabio, Salud Pública, Spain

Robert JC Steele, University of Dundee, United Kingdom

Rapporteurs Thematic groups, Conference 5.12.2019

Isabel Portillo-Villares, The Basque Health Service – The Basque Ministry of Health, Spain

David Ritchie, Association of European Cancer Leagues, Belgium

Tit Albreht, National Institute of Public Health of Slovenia, Slovenia

Marco Zappa, ISPRO Florence, Italy

Annarosa Del Mistro, Istituto Oncologico Veneto, Italy

Susanne Weg-Remers, Deutsches Krebsforschungszentrum, Germany

Tytti Sarkeala, Finnish Cancer Registry, Finland

Antonella Cardone, European Cancer Patient Coalition, Belgium

Sirpa Heinävaara, Finnish Cancer Registry, Finland

Edit Marosi, National Institute of Oncology, Hungary

Annie Scott Anderson, University of Dundee, United Kingdom

Urška Ivanus, Institute of Oncology Ljubljana, Slovenia

Robert JC Steele, University of Dundee, United Kingdom



ALL CONTRIBUTORS



Contributors from the Working Groups of the task

5.2.

Ana Molina-Barceló, FISABIO Salud Pública, Spain
Marta Hernández-García, FISABIO Salud Pública, Spain
Frédéric de Bels, Institut National du Cancer, France
Annarosa Del Mistro, Instituto Oncologico Veneto, Italy
Ahti Anttila, Finnish Cancer Registry/Cancer Society of Finland
Clarissa Bingham, Cancer Society of Finland
Deependra Singh, Finnish Cancer Registry / Cancer Society of Finland
Satu Lipponen, Cancer Society of Finland
Cecília Müller, National Public Health Center (NNK), Hungary
Péter Nagy, National Institute of Oncology (OOI), Hungary
Edit Marosi, National Institute of Oncology (OOI), Hungary
Mari Nygård, Cancer Registry of Norway (OUS)
Margarethe Meo, Cancer Registry of Norway (OUS)
Isabel Portillo, Osakidetza (Servicio Vasco de Salud / Basque Health System), Basque Country
Marco Zappa, Cancer Research and Prevention Institute (ISPRO) Florence, Italy

Ondřej Ngo, Institute of Health Information and Statistics of the Czech Republic (UZIS)
Ondrej Majek, Institute of Health Information and Statistics of the Czech Republic (UZIS)
Stephanie Xuereb, Primary Healthcare, Ministry for Health, Malta
Susanne Weg-Remers, German Cancer Research Center (DKFZ), Germany
Mirela Strandzheva, National Center for Public Health and Analyses (NCPHA), Bulgaria
Urska Ivanus, Institute of Oncology Ljubljana, Slovenia
Carolina Espina Garcia, International Agency for Research on Cancer (IARC), France
Andre Carvalho, International Agency for Research on Cancer (IARC), France
Milena Vasic, Institute of Public Health of Serbia "Dr Milan Jovanovic Batut", Serbia
David Ritchie, Association of European Cancer Leagues, Belgium
Wendy Yared, Association of European Cancer Leagues, Belgium





THANK YOU!

